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Background. Invasive candidiasis (IC) comprises candidemia and deep-seated candidiasis. Blood culture (BC) is the gold stan-
dard test, but sensitivity is low. T2Candida is a new diagnostic test. We investigated the performance of T2Candida, BC, and Candida 
mannan antigen (MAg) for detection of IC in a high-risk intensive care unit (ICU) population.
Methods. One-hundred twenty-six ICU patients at high risk of IC with sepsis despite 3 days of broad-spectrum antibiotics were 
included. Paired BC, T2Candida, and MAg were obtained twice weekly (334 sets). Patients were classified into proven, likely, possi-
ble, or unlikely IC based on patient record review.
Results. At enrollment, 92 (77%) patients were receiving antifungal therapy (mainly fluconazole 66%). Fifteen (11.9%) patients 
were positive by BC (n = 4), T2Candida (n = 11), or MAg (n = 10). The T2Candida species distribution at inclusion (Candida albi-
cans/Candida tropicalis: 8/11 [72.3%] and Candida glabrata/Candida krusei: 3/11 [27.3%]) was supported by the identification of BC 
or colonizing isolates in 10/11 cases. Patients were classified with proven (11), likely (6), possible (11), and unlikely (98) IC. Defining 
IC as proven/proven&likely/proven&likely&possible, respectively, the sensitivity was as follows: T2Candida (55%/59%/39%), BC 
(45%/29%/ 8%), and MAg (36%/41%/32%). The negative predictive value was similar across the tests for proven vs others and 
proven/likely vs others (94%–96% and 90%–95%, respectively). For test combinations including T2Candida, the sensitivity increased 
to 64%–65%, without hampering the positive predictive value.
Conclusions. In conclusion, although the diagnostic performance was modest for all the tests, the combination of T2Candida 
and BC seemed to have the best diagnostic performance, and thus implementation of T2Candida may improve the diagnosis of IC.
Keywords.  blood culture; Candida; candida mannan antigen; diagnostic performance; intensive care unit.
Invasive candidiasis (IC) comprises candidemia and deep-
seated candidiasis with or without concomitant candidemia [1]. 
The most important risk groups are patients in the intensive 
care unit (ICU) and those undergoing abdominal surgery, par-
ticularly if repeated or complicated [2–6]. Candidemia is asso-
ciated with significant morbidity, mortality, and cost [1]. The 
overall mortality is around 40% [7] but is higher among patients 
in the ICU [8].
A positive blood culture (BC) or culture from a newly (<24 
hours) placed drain establishes the diagnosis of proven IC [9]. 
However, BCs have a low sensitivity. Autopsy studies have sug-
gested a sensitivity between 21% and 71%, which is highest if 
large-volume BCs (60  mL) are obtained daily and additional 
sets are obtained during febrile episodes [10]. The use of 
mycosis culture bottles improves sensitivity for the detection 
of Candida glabrata when the BACTEC system is used and of 
polymicrobial infections when the BacT/ALERT system is used 
[2, 11–13]. However, such bottles are infrequently used.
The time to BC positivity is around 2 days [2, 14]. A 2-day 
delay in antifungal therapy has been associated with more than 
a doubling of the mortality rate in several [15, 16] but not all 
studies [2, 17, 18]. Hence, rapid diagnostic tests are warranted. 
β-D-glucan and the Candida mannan antigen (MAg) and anti-
body (MAb) tests are recommended biomarkers for the diagno-
sis and management of Candida diseases [19]. The β-D-glucan 
is a panfungal test and hence cannot distinguish between candi-
diasis and other fungal infections. The sensitivity for IC is gen-
erally high (76.7%–100.0%), but the specificity is more variable 
(40.0%–91.8%) [20–25]. Multiple sources for false positivity 
have been reported, many of which are particularly challenging 
in the ICU [20, 21, 26]. This is an important caveat and may lead 
to inappropriate antifungal treatment of patients without candi-
diasis. Candida MAg and MAb detection has been found useful 
for the detection of IC [27–31], although the performance of 
combined MAg and MAb detection was disappointing (sensi-
tivity 55% and specificity 60%) in a recent study including ICU 
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patients with severe abdominal conditions [20]. The variation 
in reported performance for this test remains unexplained, but 
in a population mainly at risk of candidiasis, a Candida-specific 
rather than panfungal test may be preferable with respect to risk 
of false-positive results and interpretation.
The T2Candida molecular test has recently been Conformité 
Européenne (CE) marked and Food and Drug Administration 
(FDA) cleared. The test detects (1) C. albicans and C. tropica-
lis, reported together as C. albicans/C. tropicalis; (2) C. glabrata, 
C. krusei, S. cerevisiae, and C. bracarensis, reported together as 
C. glabrata/C. krusei; and (3) C. parapsilosis, C. orthopsilosis, and 
C. metapsilosis, reported as C. parapsilosis. Together, these spe-
cies formed the majority (93.5%) of the Candida bloodstream 
infections in Denmark in 2012–2015 [11]. The combined sen-
sitivity and specificity of the test for detecting candidemia were 
91.1% and 99.4%, respectively, in the study that led to the FDA 
clearance [32]. Subsequent studies have confirmed a high sen-
sitivity using seeded blood samples [33] and when comparing 
the results for follow-up BCs and T2Candida tests obtained 
from pediatric and adult patients with documented candidemia 
[14, 34]. Moreover, among patients already receiving antifungal 
therapy, the T2Candida assay yielded positive results in a num-
ber of cases with negative BC [14]. Of note, studies performed 
so far included candidemic patients with or without enrichment 
of the study material with spiked blood samples. Hence the per-
formance in cases with IC without concomitant candidemia is 
largely unknown.
In this study, we compared the diagnostic performance of 
BC, T2Candida, and Candida MAg and MAb in patients at risk 
of IC in the 2 major university ICUs in a country with a high 
incidence of IC [11, 35]. To our knowledge, it is the largest and 
only non-single-center prospective study performed in a high-
risk ICU setting for comparative diagnosis of IC.
METHODS
Patients and Data Collection
In total, 126 ICU patients were included during the study period 
of October 1, 2014, to June 21, 2016. The characteristics at 2 
major university ICU units are summarized in Supplementary 
Table 1.
Inclusion Criterion
The inclusion criterion was 1 of the following: (1) initiation of 
prophylactic, empiric, or preemptive antifungal treatment; (2) 
colonization index ≥0.5; or 3)  temperature >38°C or <36°C 
despite 3  days of broad-spectrum antibiotic treatment and at 
least 2 of the following risk factors: abdominal surgery, sec-
ondary peritonitis, pancreatitis, central vein catheter (CVC) 
in place, total parenteral nutrition (TPN), dialysis, steroid 
treatment, immunosuppressive treatment, or liver transplan-
tation. Patients who fulfilled the inclusion criterion but had 
candidemia before inclusion were not excluded. Presence or 
absence of each inclusion criterion was registered, along with 
each blood sampling. Upon completion of the study, patient 
records and clinical microbiology test databases were reviewed 
for each patient. The following data were extracted: underly-
ing diseases, body temperature >38°C or <36°C, signs of sep-
sis (systolic blood pressure <90 mmHg; mean arterial pressure 
<65  mmHg; need of vasopressor infusion [epi-/norepineph-
rine] or blood pressure drop 40 mmHg from baseline), white 
blood cell count >12 000 cells/µL, confirmation of ≥3 days of 
broad-spectrum antibiotics. The microbiological tests were 
reviewed and categorized into whether Candida were isolated 
from at least 2 nonsterile sites (±3 days) and whether there was 
an alternative microbiological diagnosis.
From each patient, a 5.5-mL EDTA tube and a BC set were 
obtained simultaneously at the time of enrollment. The EDTA tube 
was used for T2Candida (T2 Biosystems, Lexington, MA) and 
for Platelia Candida MAg and Ab (Bio-Rad, Marnes-la-Coquette, 
France). BacT/ALERT (bioMérieux, Marcy l’Etoile, France) BC 
was used in Odense and BACTEC (Becton Dickinson, Franklin 
Lakes, NJ) at Rigshospitalet. Sampling was repeated twice weekly 
in Odense for as long as the patient fulfilled the enrollment crite-
ria. At Rigshospitalet, a single follow-up sample set was obtained 
after 3 days. At both hospitals, routine urine and tracheal secre-
tions were cultured at regular intervals. Additional microbiolog-
ical tests were performed as indicated by the treating physician.
Cases were classified based on vital signs and results of 
microbiological examinations within 3 days of enrollment (see 
below).
Proven IC:    either (1) growth of Candida in a BC or (2) ful-
filling all the following: (i) growth of Candida in a 
tissue biopsy or sample from a drain placed within 
24 hours, (ii) sampling from a normally sterile site 
using sterile procedures, and (iii) clinical or radio-
logical signs of infection at that site (EORTC/MSG 
criteria [9]).
Likely IC:      either (1) Candida isolated from at least 2 non-
sterile sites (±3  days) and no alternative micro-
biological diagnosis (±3  days) and fulfilling ≥1 
SIRS criterion despite 3  days of broad-spectrum 
antibacterial treatment or (2) Candida MAg 
>250 mg/L and colonized with Candida at 2 sites 
(±3 days) (adopted from [25, 36]).
Possible IC:  either (1) Candida MAg >125 mg/L and colonized 
at 2 sites (±3 days) or (2) Candida MAg >250 mg/L 
or 3)  Candida isolated from at least 2 nonsterile 
sites (±3 days) and fulfilling SIRS criteria despite 
≥3 days of broad-spectrum antibiotics.
No IC:       remaining cases.
Subsequently, we studied the medical files of all cases who were 
initially classified as either proven, likely, or possible IC or who 
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had at least 1 positive marker for IC (T2 or mannan Ag) and 
revised the classification according to results of microbiological 
analyses within 21 days of enrollment and detailed information 
on clinical course, as presented in Supplementary Table 2.
Statistical Analysis
The sensitivity, specificity, and positive (PPV) and negative 
(NPV) predictive values of the tests were assessed based on the 
sample drawn at inclusion and the subsequent sample drawn 
at day 2 or 3. If analyses of the 2 samples were discordant (ie, 
1 positive and 1 negative), the test was considered positive. 
The Fisher exact test was used to compare the proportions of 
patients receiving antifungal therapy for BC-positive vs -neg-
ative patients.
RESULTS
In total, 334 sample sets from 126 ICU patients at risk for IC 
were included during the 21-month study period. The median 
age (range) was 65.5 (16–89) years, and 72 (57%) were men. 
The majority of patients met more than 1 inclusion criterion 
(82%) and received antifungal therapy at the time of inclu-
sion (77%) (Table 1). Abdominal surgery was the most com-
mon risk factor (44%), followed by secondary peritonitis or 
immunosuppression.
Microbiology
At the time of enrollment, 15 (11.9%) patients were positive by 
BC, T2Candida, and/or MAg testing (Figure 1, Table 2). Overall, 
7/11 T2Candida-positive samples and 7/10 MAg-positive sam-
ples were from patients without a concomitant positive BC at 
the time of inclusion. Significantly fewer patients with positive 
compared with negative BCs received antifungal therapy at the 
time of inclusion (2/5 [40%] vs 90/115 [78%], P = .008). For the 
T2Candida test and the MAg test, there were no statistically sig-
nificant associations between test results and antifungal therapy 
at inclusion (7/11 [64%] vs 80/103 [78%], P =  .287, and 9/10 
[90%] vs 78/103 [76%], P = .449, respectively).
T2Candida Test Results
The species distribution among patients with initial samples pos-
itive in T2Candida was C. albicans/C.  tropicalis in 8/11 (72.3%) 
patients and C. glabrata/C. krusei in 3/11 (27.3%). The T2Candida 
test was positive for 4/5 patients with positive index BCs and for 2 
additional patients with positive BCs 2 and 4 days before inclusion, 
whereas 5 patients had negative BCs (Table 3). The species group 
reported by the T2Candida test was confirmed by the identifica-
tion of BC or colonizing isolates in 10/11 cases (Candida was not 
identified to the species level in 1 patient), although T2Candida 
failed to detect the second species at day 0 in a patient with poly-
fungal infection (Table 3). T2Candida was negative in the patient 
with C.  kefyr candidemia, a species that is not included in the 
panel, and was invalid in 9/126 (7.1%) patients at enrollment.
In 4 BC-negative patients, a single follow-up sample was pos-
itive by T2Candida, 3 of these with C. parapsilosis in the absence 
of concomitant C. parapsilosis colonization or other indication 
of IC (Table 3). These 3 cases were likely false positives. The 
fourth patient became positive with C. glabrata/C. krusei, MAg, 
and MAb at day 4. Including these, the overall species distribu-
tion as determined by T2Candida was C. albicans/C. tropicalis 
8/15 (53%), C. glabrata/C. krusei 4/15 (27%), and C. parapsilosis 
3/15 (20%).
Table 1. Baseline Characteristics of the Study Population (126 Patientsa)
Male, No. (%) 72 (57)
Age, median (IQR), y 65.5 (53–75)
Inclusion criterion, %  
Initiation of antifungal therapy 84
Colonization index ≥ 0.5 33
Fever despite antibiotics combined with 
the presence of at least 2 risk factors
80
Risk factors, No. (%)  
Central venous catheter 112/124 (90)
Parenteral nutrition 24/121 (20)
Dialysis 26/122 (21)
Steroids 32/121 (26)
Abdominal surgery 54/123 (44)
Secondary peritonitis 20/120 (17)
Pancreatitis 6/120 (5)
Immunosuppressed 19/121 (16)
Liver transplantation 1/121 (0.8)
Antifungal Rx at time of inclusion, No. (%)  
None 27/119 (23)
Fluconazoleb 76/119 (63)
Other azole 3/119 (3)
Echinocandinb 14/119 (12)
Abbreviation: IQR, interquartile range.
aData missing for some patients as indicated by varying denominators.
bOne patient received caspofungin and fluconazole combination therapy.
3
1*
2
4
BC pos.
n = 5
MAg pos.
n = 10
T2 pos.
n = 11
2 3
Figure 1. Positive diagnostic samples at the time of inclusion in the study. aBlood 
culture with Candida kefyr, which is not included in the panel of the T2Candida 
test. Abbreviations: BC,  blood culture; MAg,  mannan antigen; Pos., positive; 
T2, T2Candida.
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Candida Mannan Ag and Ab
The MAg test was positive in 3/5 patients with positive BC at 
enrollment, including the patient with C.  kefyr candidemia 
(Table 3). Seven additional patients were MAg positive at 
enrollment, 4 of whom were T2Candida positive and 1 of 
whom had been BC positive 5 and 7 days earlier. During the 
follow-up period, 4 additional BC-negative patients changed 
to MAg positive (2 of whom also developed MAb), whereas 5 
patients became MAb positive during follow-up (1 of whom 
was BC positive at inclusion, 4 of whom were T2 positive, and 4 
of whom were or subsequently became MAg positive).
Kinetics of BC and Biomarker Results
T2Candida stayed positive longer (mean [range], 3.2 [0–5] days) 
than BC. Eight of 9 patients with positive MAg and follow-up 
samples remained MAg positive during the entire observation 
period (up to 20 days) (Table 3).
Clinical Classification and Performance of Diagnostic Tests
The numbers of patients classified as proven, likely, or possible 
IC were 11 (8.7%), 6 (4.8%), and 11 (8.7%), respectively (Table 4; 
Supplementary Table 2). Abdominal IC was the most common 
manifestation (16/22 [72.7%]) among BC-negative patients with 
proven (2/5), likely (4/6), or possible IC (10/11), respectively. 
Significantly fewer patients with proven IC received antifungal 
treatment (AF) before enrollment (5/11) than among likely and 
unlikely cases (6/6, P = .004, and 82/95, P = .047) (Table 4).
The sensitivity was higher for T2Candida compared with 
BC and MAg for proven IC (55% vs 45% and 36%), for proven 
or likely IC (59% vs 29% and 41%), and for proven, likely, or 
possible IC (39% vs 8% and 32%), respectively, compared with 
others (Table 5); however, as the number of cases of IC was 
limited, these differences did not reach statistical significance. 
When combining the diagnostic tests, the sensitivity increased 
to 64%–65% for test combinations including T2Candida com-
pared with 53%–55% for BC+MAg for proven vs others and 
proven/likely vs others. The specificity was high and above 90% 
for all tests and test combinations except T2Candida-BC-MAg 
triple testing for proven vs others. The PPV was higher for 
T2Candida than for MAg (50% vs 36% for proven and 83% vs 
64% for proven/likely vs other, respectively). The negative pre-
dictive value was similar across the tests (94%–96% for proven 
and 90%–95% for proven/likely, respectively) but somewhat 
lower if including possible cases of IC (81%–88%). Overall, 
T2Candida combined with BC seemed to have the best diag-
nostic performance for proven/likely IC compared with other 
single tests or test combinations.
DISCUSSION
In this study comparing the performance of diagnostic tests 
among high-risk ICU patients, the highest sensitivity and 
NPV for IC were found for T2Candida and for test combina-
tions including T2Candida. No single test or test combination 
resulted in a sensitivity above 65% for IC, but the combination 
of T2Candida and BC seemed to have the best diagnostic per-
formance for proven/likely IC. So far, the only other study pro-
spectively enrolling patients before the establishment of an IC 
diagnosis found the T2Candida test positive in 4/6 patients with 
positive BCs, in line with the 4/5 found in our study [32]. In that 
study, a 91.1% sensitivity and 99.4% specificity for T2Candida 
compared with BC were estimated, enriching the sample size 
with 250 samples spiked with Candida cells at concentrations 
similar to what is expected during (untreated) candidemia [32]. 
We estimated test performance based on the clinical classifica-
tion of high-risk patients, the majority of whom were suffering 
from deep-seated IC. We speculate that this difference in study 
design and the fact that many patients had received several days 
of antifungal therapy before enrollment may in part explain the 
lower performance of the T2Candida test in our setting.
The expected IC rate is around 10% among severely ill high-risk 
ICU patients [37]. In this study, 8.7% were classified with proven 
IC and additional 4.8% with likely IC. In this context, the rate of 
BC-proven candidiasis was notably low (4%). Most of our patients 
received antifungal therapy at the time of enrollment, with fluco-
nazole being the predominating compound. Notably, none of the 
Table 2. Comparison of Blood Culture, T2Candida, and Candida Mannan Antigen Results for the Initial Samples Taken at the Time of Inclusion
 Blood Culture
T2Candida Candida MAg
T2Candida and/or 
MAg
Candida albicans/tropicalis Candida glabrata/krusei Neg. Invalid Pos. Int. Neg. +/+ +/− −/+ −/−
C. albicans (1) 1 1 1
C. glabrata (1)  1     1  1   
C. tropicalis (1) 1    1   1    
C. tropicalis & C. glabrata (1) 1  -a  1   1    
C. kefyr (1)   1  1     1  
Neg-BC (121) 5 2 107 7 7 7 107 4 3 3 111
In total (126) 8 3 108 7 10 7 109 6 5 4 111
Abbreviations: Int., intermediate; MAg, mannan antigen; Neg., negative; Neg-BC, blood culture without growth of Candida; Pos., positive.
aThe C. glabrata found in the initial blood culture was reported on day 4 but not on day 0 by the T2Candida test.
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patients with candidemia had received AF for ≥24 hours at the 
time of inclusion. Fluconazole (20 mg/L) reduced overall BC sen-
sitivity by 7.5%–12.5% in a recent laboratory experiment [38]. In 
line with these findings, significantly fewer patients with proven 
infection received prior antifungal therapy in our study, a diagnosis 
that requires a positive culture from blood or a sterile site. In con-
trast, fluconazole was observed not to impact the sensitivity of the 
T2Candida assay in the above-mentioned laboratory study [38]. 
We observed a trend toward a lower T2Candida-positive rate for 
patients receiving antifungal therapy before sampling, suggesting 
that T2Candida sensitivity may also be reduced during antifungal 
therapy. Fluconazole therapy may lower the fungal load or clear 
the bloodstream despite not clearing the foci of patients with deep-
seated candidiasis and hence result in a lower T2Candida sensitiv-
ity that is not observed in studies of spiked blood. It may therefore 
be advisable to initiate diagnostic testing before initiation of anti-
fungals whenever feasible.
The species group provided for positive T2Candida test 
results was in agreement with the Candida species diagnosis 
established by culture from blood or other sites for patients 
with IC. The overall T2Candida species distribution including 
positives during follow-up was C. albicans/C.  tropicalis 53%, 
C. glabrata/C. krusei 27%, and C. parapsilosis 20%. In compar-
ison, these species accounted for 52%, 36%, and 3%, respec-
tively, in the national surveillance program in 2012–2015 
[11]. C.  parapsilosis is a skin and biofilm–associated organ-
ism. None of the 3 patients with a positive C.  parapsilosis 
T2Candida result were diagnosed as IC or colonized with 
C. parapsilosis by culture. We therefore regard these findings 
as contaminations, illustrating the importance of thoroughly 
decontaminating the skin or catheter before blood draws 
for T2Candida. In settings with a higher true prevalence of 
C. parapsilosis infections like in neonates and in endemic areas 
such as Latin America, Southern Europe, and Asia, it may be 
difficult to differentiate clinically relevant C. parapsilosis find-
ings from contaminations, potentially leading to unnecessary 
use of antifungal therapy [39].
T2Candida is an expensive diagnostic tool. At the time of writ-
ing, the price in our country for a test kit is US$300 per sample, 
and an annual fee for a service contract of US$15 500. Although 
cost analyses have suggested lower candidemia-related inpatient 
costs and mortality with implementation of the T2Candida test 
[40], cost may be prohibitive in some settings, particularly at a 
time of declining cost for the echinocandins. The combination of 
MAg with BC was superior to BC alone. However, in addition to 
being less sensitive compared with T2Candida alone and when 
combined with BC, a drawback is that species identification is not 
provided for MAg-positive samples to inform whether the species 
is a likely target for de-escalation to fluconazole once the patient 
is stable.
Table 4. Performance of Blood Culture, T2Candida, and Mannan Antigen Based Upon the 2 Initial Blood Sample Sets for Patients Classified With Proven 
(11), Likely (6), Possible (11), or Unlikely (98) Invasive Candidiasis
Final Classification No. of Patients No. w/ Prior AF BC Pos T2 Pos MAg Pos
Proven 11 5/11 5/11 6/11 4/11
Candidemia within ±3 d of inclusion 6 2a,a 5/6 5/6 3/6
Abdominal candidiasis incl. aortaprothesis 1 0 0 0 0
Abdominal candidiasis 1 1e 0 1/1 1/1
Mediastinal or pleural candidiasis 2 2b,e 0 0 0
Polymicrobial necrotizing fasciitis 1 0 0 0 0
Likely 6 6/6 0/6 4/6 3/6
Abdominal candidiasis & prior proven abdominal candidiasis 3 3a,d,e 0 1/3 0
Abdominal candidiasis 1 1c 0 1/1 1/1
Pulmonary candidiasis in hematological Pt 1 1e 0 1/1 1/1
Tissue candidiasis 1 1a 0 1/1 1/1
Possible 11 10/11 0/11 1 (&1 d4)/11 2/11
Abdominal candidiasis 8 7a,a,b,b,b,e,e 0 1 (&1 d4)/8 1/8
Abdominal candidiasis & prior proven candidemia, d –5 & –7 1 1c 0 0 1/8
Abdominal candidiasis & proven, d +4 1 1e 0 0 0
Renal candidiasis & prior proven 1 1e 0 0 0
Unlikely 98 82/95f 0/98 1g /98 2/98
Information on prior systemic antifungal therapy at inclusion is indicated (No. w/ Prior AF).
Abbreviations: AF, antifungal treatment; BC, blood culture; MAg, mannan antigen (pg/mL); T2, T2Candida.
aDuration of AF before inclusion: <1 day.
bDuration of AF before inclusion: 1–3 days.
cDuration of AF before inclusion: 4–7 days.
dDuration of AF before inclusion: >7 days.
eNo information on duration of AF before inclusion.
fInformation on prior antifungal therapy was missing for 3/98 patients.
gCandida parapsilosis.
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The time to negativity was longer for the T2Candida test than 
for BC, supporting recent findings [41]. This may suggest that 
whereas the appropriate duration of therapy after resolution 
of symptoms and BC negativity is 14 days, this may be shorter 
after resolution of symptoms and T2Candida negativity [42]. 
In contrast, the mannan antigen remained positive throughout 
the observation period and up to 14 days after BC documented 
clearance of the bloodstream and thus should not alone prompt 
continued antifungal therapy.
This study has limitations. First and foremost, the number 
of proven and likely cases was limited, and more than half of 
the proven IC cases were BC negative at the time of inclusion, 
suggesting a low amount of circulating Candida cells. Therefore, 
numbers were insufficient for statistical comparative analysis of 
the diagnostic tests. In the absence of a reliable gold standard for 
the diagnosis of IC, classification of patients was done adopting 
the EORTC/MSG definitions for proven infection and criteria 
adopted from 2 recent studies for likely and possible IC [9, 25, 
36]. A  positive blood culture defined proven infection, and a 
highly positive MAg in a colonized patient with clinical signs 
and symptoms defined likely IC, whereas a positive T2Candida 
did not. Consequently, the relative diagnostic performance 
of T2Candida compared with BC and MAg may have been 
underestimated. Most of the patients with deep-seated IC were 
patients with complicated infections receiving broad-spectrum 
antibiotics in whom it is difficult to dissect the clinical signif-
icance of the findings of Candida in microbiological samples. 
Finally, colonization was difficult to compare, as neither sam-
pling nor mycologic examination was standardized.
In conclusion, our study underscores the complexity associated 
with diagnosing IC. Most patients were BC negative, probably in 
part because the majority were already on fluconazole prophy-
laxis, as recommended in a multimorbid high-risk population. 
T2Candida was the biomarker that contributed the most to improv-
ing the diagnostic sensitivity while retaining a good specificity and 
NPV. This makes it a promising addition to the diagnostic arma-
mentarium. However, our study also suggests that maximal benefit 
of diagnostic efforts may require that sampling is initiated as early as 
possible, preferably before initiation of antifungal therapy, when the 
sensitivity and NPV of T2Candida and BC testing are maximal and 
probably sufficient for excluding IC.
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